GlassScriptPhysician profile
Sherry X Ma
NPI 1275649048
$1,698.18
in general payments reported to CMS, 2019-2025
15 companies · $481 in 2025
The $481 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $118 · 2022: $239 · 2023: $111 · 2024: $749 · 2025: $481.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,341.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,340.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $183.70 | 2023-2024 | Kisunla, Emgality, Reyvow |
| Emd Serono, INC. | $148.11 | 2024 | |
| Amgen INC. | $144.72 | 2023-2025 | Uplizna, Aimovig |
| Abbvie INC. | $137.31 | 2024-2025 | |
| Sk Life Science, INC. | $129.88 | 2023-2025 | Xcopri |
| Teva Pharmaceuticals USA, INC. | $124.86 | 2025 | Austedo Xr |
| Janssen Biotech, INC. | $124.86 | 2025 | |
| Janssen Pharmaceuticals, INC | $124.77 | 2022 | |
| Genzyme Corporation | $118.35 | 2021 | |
| Eisai INC. | $115.57 | 2024 | |
| Celgene Corporation | $108.32 | 2024 | Zeposia |
| E.R. Squibb & Sons, L.L.C. | $102.36 | 2024 | Zeposia |
| Neurocrine Biosciences, INC. | $95.19 | 2022 | |
| Pfizer INC. | $21.18 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sherry Ma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.